[PDF] psu.edu

[PDF][PDF] Hematological and molecular response evaluation of CML patients on imatinib

A Gupta, K Prasad - JAPI, 2007 - Citeseer
Abstract Background: The BCR-ABL tyrosine kinase is a well-validated therapeutic target in
Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase …
被引用次数：26 相关文章

Hematological and molecular response evaluation of CML patients on imatinib.

A Gupta, K Prasad - 2007 - pesquisa.bvsalud.org
BACKGROUND: The BCR-ABL tyrosine kinase is a well-validated therapeutic target in
Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase …

Hematological and molecular response evaluation of CML patients on imatinib.

A Gupta, K Prasad - The Journal of the Association of Physicians of …, 2007 - europepmc.org
Background The BCR-ABL tyrosine kinase is a well-validated therapeutic target in Chronic
Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase inhibitor is …

Hematological and molecular response evaluation of CML patients on imatinib

A Gupta, K Prasad - The Journal of the Association of …, 2007 - pubmed.ncbi.nlm.nih.gov
Background The BCR-ABL tyrosine kinase is a well-validated therapeutic target in Chronic
Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase inhibitor is …

[引用][C] Hematological and molecular response evaluation of CML patients on imatinib

A GUPTA, K PRASAD - … of Physicians of …, 2007 - Association of Physicians of India